文献速递淋巴瘤

高级别B细胞淋巴瘤非特指型(HGBL-NOS)在临床病理和遗传学上比DLBCL更类似于DLBCL/HGBL-DH

High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL.
PubMed 文献 · Leukemia · 2022-12-13

该研究分析了136例HGBL-NOS患者的临床病理和遗传学特征,并与224例DLBCL/HGBL-DH和217例DLBCL患者进行比较。HGBL-NOS患者的中位总生存期(28.9个月)与DLBCL/HGBL-DH相似(p=0.48),但劣于DLBCL(p=0.03)。R-EPOCH诱导方案相比R-CHOP与改善的总生存期相关。

要点

  • HGBL-NOS患者中43%存在MYC重排(MYC-R)。
  • HGBL-NOS的中位OS为28.9个月,与DLBCL/HGBL-DH相似(p=0.48),但劣于DLBCL(p=0.03)。
  • R-EPOCH诱导相比R-CHOP与改善的OS相关。

核心结论

  • HGBL-NOS的临床病理特征和基因表达谱更类似于DLBCL/HGBL-DH而非DLBCL。
  • HGBL-NOS病例常携带MYC-R并具有DH样特征(DH-like-Sig+)。
  • R-EPOCH诱导在HGBL-NOS中似乎与相比标准R-CHOP改善的OS相关。

研究设计与样本

  • 研究纳入136例HGBL-NOS患者,并与224例DLBCL/HGBL-DH(依据第5版WHO定义)和217例DLBCL患者进行比较。
  • 对部分HGBL-NOS病例进行了全转录组分析。

主要发现

  • HGBL-NOS患者的临床特征与DLBCL/HGBL-DH患者相似。
  • HGBL-NOS中43%存在MYC重排(MYC-R)。
  • HGBL-NOS患者的中位OS为28.9个月,与DLBCL/HGBL-DH相似(p=0.48),但劣于DLBCL患者(p=0.03)。
  • R-EPOCH诱导相比R-CHOP与改善的OS相关。
  • MYC-R、淋巴瘤病史和高IPI是HGBL-NOS患者的独立不良预后因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-grade B-cell lymphoma, not otherwise specified (HGBL-NOS) is rare and data focused on these neoplasms is lacking. We studied the clinicopathologic and genetic features of 136 HGBL-NOS patients and compared them to patients with DLBCL/HGBL-DH (n = 224, defined by 5th Edition WHO) and DLBCL (n = 217). HGBL-NOS patients had clinical features similar to DLBCL/HGBL-DH patients. MYC rearrangement (MYC-R) was present in 43% of HGBL-NOS. With induction regimen similar to DLBCL/HGBL-DH patients, HGBL-NOS patients had a median overall survival (OS) of 28.9 months, similar to DLBCL/HGBL-DH (p = 0.48) but inferior to DLBCL patients (p = 0.03). R-EPOCH induction was associated with improved OS compared with R-CHOP. MYC-R, history of lymphoma, and high IPI were independent adverse prognostic factors in HGBL-NOS patients. Whole transcriptome profiling performed on a subset of HGBL-NOS cases showed a profile more similar to DLBCL/HGBL-DH than to DLBCL; 53% of HGBL-NOS had a DH-like signature (DH-like-Sig) and were enriched for MYC-R. DH-like-Sig+ HGBL-NOS patients had a poorer OS than DH-like-Sig-negative patients (p = 0.04). In conclusion, HGBL-NOS has clinicopathologic features and a gene expression profile more similar to DLBCL/HGBL-DH than to DLBCL. Cases of HGBL-NOS frequently carry MYC-R and have a DH-like-Sig+. R-EPOCH induction in HGBL-NOS appears associated with improved OS compared with standard R-CHOP.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Li S, Qiu L, Xu J, et al. High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL. Leukemia. 2022. PMID: 36513804. doi:10.1038/s41375-022-01778-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。